Clinical trials: Dual Diagnosis
Rhinitis, Allergic, Perennial
Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to < 15 years with perennial allergic rhinitis will be evaluated compared with placebo.
- Trial name
- NCT01630135
- Testing
- Fluticasone furoate
- Where
- 22 sites in Japan
- Volunteers
- 261 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.
- Trial name
- NCT02337725
- Testing
- TVP-1012
- Where
- 55 sites in Japan
- Volunteers
- 244 people
- Sponsor
- Takeda
Congestive Heart Failure, LV Dysfunction
Dual Site Left Ventricular (LV) Pacing
The purpose of this study is to compare Dual LV (left ventricular) pacing to standard single LV pacing (BiV pacing) to see if Dual LV pacing: 1. Improves the way the heart's left ventricle functions 2.
- Trial name
- DIVA (NCT00944125)
- Testing
- Dual Site LV Pacing, BiV Pacing
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Obsessive-compulsive Disorder, Ocd
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
Obsessive-compulsive disorder (OCD) affects 2-3% of the population and leads to a great deal of suffering. Many patients benefit from established treatments, the mainstay of which are cognitive behavioral therapy and a group of…
- Trial name
- NCT00523718
- Testing
- riluzole
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Heart Failure, Systolic, Diabetes Mellitus, Type 2
Treatment of Diabetes in Patients With Systolic Heart Failure
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption [VO2]) and ventilator efficiency (minute ventilation…
- Trial name
- NCT02920918
- Testing
- Canagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Virginia Commonwealth University
Macular Degeneration
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to…
- Trial name
- COBALT (NCT00499590)
- Testing
- bevasiranib, ranibizumab
- Where
- 60 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- OPKO Health, Inc.
Type 2 Diabetes
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01646320
- Testing
- Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
- Where
- 66 sites in United States, Czechia and 6 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis
A study to evaluate safety and tolerability and characterize the pharmacokinetic (PK) profile of rozibafusp alfa following multiple dose administration in adults with rheumatoid arthritis (RA).
- Trial name
- NCT03156023
- Testing
- Rozibafusp Alfa
- Where
- 4 sites in United States, Germany
- Volunteers
- 34 people
- Sponsor
- Amgen
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week…
- Trial name
- NCT00740779
- Testing
- Silodosin 8 mg, Silodosin 4 mg
- Where
- 22 sites in United States
- Volunteers
- 153 people
- Sponsor
- Watson Pharmaceuticals
Spondyloarthropathies
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial…
- Trial name
- NCT01087762
- Testing
- CZP 200 mg Q2W, CZP 400 mg Q4W
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 325 people
- Sponsor
- UCB BIOSCIENCES GmbH
Obesity, Overweight
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066…
- Trial name
- NCT03100058
- Testing
- LIK066
- Where
- 83 sites in United States, Austria and 5 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Celiac Disease
Assessment of KAN-101 in Celiac Disease (ACeD)
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2.
- Trial name
- NCT04248855
- Testing
- KAN-101
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Binge Eating Disorder
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
- Trial name
- NCT03107026
- Testing
- dasotraline 4mg, dasotraline 6mg
- Where
- 50 sites in United States
- Volunteers
- 491 people
- Sponsor
- Sumitomo Pharma America, Inc.
Osteoarthritis of the Knee
Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab
The purpose of this study is to determine if an anti-inflammatory drug, called infliximab, will reduce inflammation in the synovial lining in patients with an early stage of osteoarthritis of the knee.
- Trial name
- NCT01144143
- Testing
- Infliximab, Standard of Care: Methylprednisolone acetate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Herbert Lindsley, MD
Mild Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease.
- Trial name
- NCT03186989
- Testing
- IONIS MAPTRx
- Where
- 13 sites in Canada, Finland and 4 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
Hyperkalemia
Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
Acute Phase: It is hypothesized that ZS (zirconium silicate) is more effective than placebo control (alternative hypothesis) in lowering S-K levels in subjects with S-K between 5.0 - 6.5 mmol/l versus no difference between ZS and…
- Trial name
- NCT01737697
- Testing
- Zirconium silicate (acute phase), Zirconium silicate (subacute phase)
- Where
- 44 sites in United States, Australia
- Volunteers
- 754 people
- Sponsor
- ZS Pharma, Inc.
Bipolar Disorder I, Bipolar Disorder II
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Trial name
- NCT03692910
- Testing
- SAGE-217
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in participants with lower risk MDS and low red blood cell transfusion burden.
- Trial name
- NCT03263091
- Testing
- Roxadustat
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 184 people
- Sponsor
- Kyntra Bio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.